Is Veeva Systems (NYSE:VEEV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Veeva Systems at current levels.
The Salesforce divorce is the whole story, and Veeva is winning it faster than the tape suggests.
Where VEEV is headed
By mid-2027, Veeva will have completed one of the cleanest platform migrations in enterprise software history. Every major pharma customer (Pfizer, Merck, Novartis, AstraZeneca, Lilly) will be running Vault CRM on Veeva's own infrastructure rather than Salesforce's, and the September 2025 deadline that once looked like an existential cliff will instead read as the moment Veeva graduated from a vertical app vendor into a full life-sciences operating system. The CRM migration is the headline, but the real prize is what gets sold alongside it: Crossix analytics, Link data, Compass patient data, and the Data Cloud stack that competes directly with IQVIA's $15B data business at a fraction of the cost.
Read the full Compass Direction on VEEV
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios.
See the full VEEV analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Veeva Systems (NYSE:VEEV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Veeva Systems at current levels. The Salesforce divorce is the whole story, and Veeva is winning it faster than the tape suggests.
What is VEEV's Compass Score?
Veeva Systems scores 51/100 on Alexandria's Compass, placing it in the "Neutral" tier. Scores blend eight factors and update weekly.
What is the price target for VEEV?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the VEEV page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.